MA firm tied to closed pharmacy issues recall - WSMV News 4

MA firm tied to closed pharmacy issues recall

Posted: Updated:

A company with the same founders as the specialty pharmacy linked to deadly nationwide meningitis outbreak said it is recalling all its products.

In a statement Wednesday, Ameridose said the voluntary recall comes after FDA officials told the company it must improve its sterility testing. The Westborough company said it has no reports of problems with its products, or any impurities, but issued the recall "out of an abundance of caution."

The company did not say how many products it is recalling.

Ameridose agreed to shut down for inspection earlier this month after tainted steroids from the New England Compounding Center were linked to an outbreak that has killed 28.

Ameridose and NECC were both founded by brothers-in-law Barry Cadden and Greg Conigliaro. Ameridose says it is a separate entity with distinct management.

According to the company, the Food and Drug Administration told Ameridose it wants to improve the company's sterile testing process, which was a key problem at NECC.

More than a dozen times, the company shipped medications without waiting for test results to show they were safe.

Some of those medicines sparked a fungal meningitis outbreak that sickened dozens in states across the country, along with 74 people in Tennessee.

Ameridose supplied HCA hospitals throughout the state.

In a statement to Channel 4 News, HCA said:

"We are aware of the Ameridose recall, and our affiliated facilities that have their products are pulling them. We have been working closely with our facilities during the last few weeks to identify alternative options. We believe they have sufficient supplies to meet the needs of our patients at this time."

Copyright WSMV 2012 (Meredith Corporation). All rights reserved. The Associated Press contributed to this report.

Powered by Frankly
Powered by WorldNow CNN
All content © 2018, WSMV; Nashville, TN. (A Meredith Corporation Station) . All Rights Reserved.
For more information on this site, please read our Privacy Policy, and Terms of Service, and Ad Choices.